Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

ClinicalTrials.gov ID: NCT00297102

Public ClinicalTrials.gov record NCT00297102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study

Study identification

NCT ID
NCT00297102
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,523 participants

Conditions and interventions

Interventions

  • Roflumilast Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Jun 30, 2008
Completion
Aug 31, 2008
Last update posted
Jan 15, 2017

2006 – 2008

United States locations

U.S. sites
47
U.S. states
26
U.S. cities
46
Facility City State ZIP Site status
Altana Pharma/Nycomed Investigational Site Fullerton California 92385
Altana Pharma/Nycomed Investigational Site Los Angeles California 90025
Altana Pharma/Nycomed Investigational Site Los Angeles California 90048
Altana Pharma/Nycomed Investigational Site Palmdale California 93551
Altana Pharma/Nycomed Investigational Site Rancho Mirage California 92270
Altana Pharma/Nycomed Investigational Site San Diego California 92120
Altana Pharma/Nycomed Investigational Site Bay Pines Florida 33708
Altana Pharma/Nycomed Investigational Site Miami Florida 33176
Altana Pharma/Nycomed Investigational Site Panama City Florida 32405
Altana Pharma/Nycomed Investigational Site Atlanta Georgia 30309
Altana Pharma/Nycomed Investigational Site Marietta Georgia 30060
Altana Pharma/Nycomed Investigational Site Hines Illinois 60141
Altana Pharma/Nycomed Investigational Site South Bend Indiana 46617
Altana Pharma/Nycomed Investigational Site Lebanon Kentucky 40291
Altana Pharma/Nycomed Investigational Site Metairie Louisiana 70006
Altana Pharma/Nycomed Investigational Site New Orleans Louisiana 70112
Altana Pharma/Nycomed Investigational Site Slidell Louisiana 70461
Altana Pharma/Nycomed Investigational Site Sunset Louisiana 70584
Altana Pharma/Nycomed Investigational Site Bangor Maine 04401
Altana Pharma/Nycomed Investigational Site Baltimore Maryland 21224
Altana Pharma/Nycomed Investigational Site North Dartmouth Massachusetts 02777
Altana Pharma/Nycomed Investigational Site Edina Minnesota 55435
Altana Pharma/Nycomed Investigational Site Minneapolis Minnesota 55407
Altana Pharma/Nycomed Investigational Site Chesterfield Missouri 63017
Altana Pharma/Nycomed Investigational Site St Louis Missouri 63117
Altana Pharma/Nycomed Investigational Site Billings Montana 59102
Altana Pharma/Nycomed Investigational Site Missoula Montana 59804
Altana Pharma/Nycomed Investigational Site Lincoln Nebraska 68510
Altana Pharma/Nycomed Investigational Site Omaha Nebraska 68114
Altana Pharma/Nycomed Investigational Site Reno Nevada 89502
Altana Pharma/Nycomed Investigational Site Cherry Hill New Jersey 08003
Altana Pharma/Nycomed Investigational Site Springfield New Jersey 07081
Altana Pharma/Nycomed Investigational Site New York New York 10029
Altana Pharma/Nycomed Investigational Site Winston-Salem North Carolina 27103
Altana Pharma/Nycomed Investigational Site Cincinnati Ohio 45241
Altana Pharma/Nycomed Investigational Site Columbus Ohio 43215
Altana Pharma/Nycomed Investigational Site Toledo Ohio 43614
Altana Pharma/Nycomed Investigational Site Youngstown Ohio 44501
Altana Pharma/Nycomed Investigational Site Lake Oswego Oregon 97035
Altana Pharma/Nycomed Investigational Site Philadelphia Pennsylvania 19140
Altana Pharma/Nycomed Investigational Site Cranston Rhode Island 02920
Altana Pharma/Nycomed Investigational Site East Providence Rhode Island 02914
Altana Pharma/Nycomed Investigational Site Austin Texas 78750
Altana Pharma/Nycomed Investigational Site Dallas Texas 75231
Altana Pharma/Nycomed Investigational Site Charlottesville, VA Virginia 22908
Altana Pharma/Nycomed Investigational Site Bellingham Washington 98225
Altana Pharma/Nycomed Investigational Site Marietta Wisconsin 53717

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 132 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00297102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 15, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00297102 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →